Fish Collagen Peptide Food Supplement on Weight and Body Composition (NATICOL)

Effect of a Fish Collagen Peptide Food Supplement on the Weight and Body Composition of Healthy Volunteers in Overweight

Fish collagen hydrolysates or peptides orally administered have been investigated in recent clinical trials in human health. These peptides have been evaluated in various biological and medical fields including skin aging, osteoarticular apparatus, muscle and more recently in energy metabolism in both animals and humans.

However, very few studies investigated the effect of fish collagen peptides on weight, body composition or glycemic response. Recently, it has been shown that the consumption of fish collagen peptides (Naticol®) limits weight gain and increase in fat mass in a mouse model made obese by a hyperlipidic diet. Since these results have never been observed in humans, this pilot study proposes to answer this question.

Study Overview

• Status: Completed
• Conditions: Weight Management; Food Complement
• Intervention / Treatment: Dietary supplement: Placebo supplement; Dietary supplement: Naticol supplement

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Nord
    • Lille, Nord, France, 59019
      • NutrInvest - Institut Pasteur de Lille

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Men in overweight (BMI between 25kg/m² and 30kg/m²)
• Aged from 18 and 60 years
• Having signed the informed consent form;
• Susceptible to follow the constraints generated by the study;

Exclusion Criteria:

• Subject treated for type 1 or 2 diabetes, or for any other metabolic disorder (severe dyslipidemia: TG> 3 g / L and total cholesterol> 2.5 g / L);
• Subject with untreated and uncorrected high blood pressure;
• Subject with untreated or uncorrected dysthyroidism by drug therapy;
• Subject with a serious general illness that may prevent his or her ability to complete the trial or that could bias the results of the study;
• Subject consuming antibiotic treatment in the month prior to inclusion;
• Subject treated with steroidal anti-inflammatory drugs, anabolic steroids, anticoagulants or corticosteroids;
• Subject knowing allergy to fish or fish collagen;
• Subject taking any dietary supplement or drug that may interact with the results of the study or that could alter the bioavailability of the product under study;
• Subject following or having followed a low-calorie diet (energy intake <1500 kcal / day) in the 3 months preceding inclusion and / or likely to undertake this diet during the test;
• Subject having lost more than 5% of his initial weight during the last 3 months;
• Subject following a special diet: eg. vegetarian, macrobiotic diet, high protein diet;
• Subject with diagnosed eating disorders (anorexia, bulimia);
• Subject with gastrointestinal malabsorption such as celiac disease, Crohn's disease or lactose intolerance;
• Subject having undergone bariatric surgery;
• Subject with excessive alcohol consumption at more than 3 drinks a day ;
• Subject planning to modify his tobacco consumption (eg weaning) or his level of physical activity (significant increase) before the end of the intervention period;
• Subject having an aversion to the grapefruit aroma;
• Subject unable to understand or adhere to the protocol;
• Subject participating in another clinical study or exclusion period from another study;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo supplement; Consumption of a non active food complement during 3 months.	Dietary supplement: Placebo supplement; Consumption of a non active food complement during 3 months. Tests performed : 2 blood tests :; 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA); 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.
Active Comparator: Naticol supplement; Consumption of the active food complement during 3 months containing Naticol.	Dietary supplement: Naticol supplement; Consumption of the active food complement during 3 months containing Naticol. Tests performed : 2 blood tests :; 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA); 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Weight of participants	Weight is expressed in kilograms	0 and 3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body composition par DXA analysis	Fat mass is expressed in kg and percent, muscle mass in kg and percent.	0 and 3 months
Waist circumference	Data are expressed in centimeters	0 and 3 months
Lipid profile in plasma	Total cholesterol, HDL cholesterol, LDL cholesterol, and Triglycerides. Data are expressed in g/L and in mmol/L	0 and 3 months
Glycemia level in plasma	Data are expressed in g/L and mmo/L	0 and 3 months
Insulin level in plasma	Data are expressed in μU/ml	0 and 3 months
HOMA index	This index indicates the insulin resistance and was calculated as follow : HOMA [(glycémie mmol/l X insulinémie μU/ml) à jeun / 22,5]	0 and 3 months
Physical activity intensity	Score obtained via Ricci and Gagnon questionnaire. The questionnaire contains 9 questions ; score could be between 9 and 45 points.; under 18 points : inactive behavior; between 19 and 35 points : active behavior; over 35 points : very active behavior	0 and 3 months
Pro-inflammatory cytokines concentration	Assay for TNFalpha, IL-1beta and IL-6 in plasma	0 and 3 months
Microbiota analysis	Rate comparison of different bacteria families	0 and 3 months
Height	centimeters
Body mass index	kg/m²	0 and 3 months

Collaborators and Investigators

• Sponsor: Institut Pasteur de Lille

Study record dates

Study Major Dates

• Study Start (Actual): January 14, 2019
• Primary Completion (Actual): June 30, 2019
• Study Completion (Actual): July 30, 2019

Study Registration Dates

• First Submitted: March 11, 2019
• First Submitted That Met QC Criteria: March 11, 2019
• First Posted (Actual): March 13, 2019

Study Record Updates

• Last Update Posted (Estimate): December 7, 2022
• Last Update Submitted That Met QC Criteria: December 6, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Body Weight
• Other Study ID Numbers: 2018-A02490-55

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No